PHC Holdings Corporation (PHCCF)
| Previous Close | 8.10 |
| Open | 8.10 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 8.10 - 8.10 |
| 52 Week Range | 8.10 - 11.30 |
| Volume | |
| Avg. Volume | 8 |
| Market Cap | 1.02B |
| Beta (5Y Monthly) | 0.85 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.92 |
| Earnings Date | May 10, 2024 |
| Forward Dividend & Yield | 0.48 (5.87%) |
| Ex-Dividend Date | Mar 28, 2024 |
| 1y Target Est | N/A |
Business WireEpredia and NovaScan Announce Intent to Enter U.S. Distribution Agreement for MarginScan™ Device for Non-Melanoma Skin Cancer Detection
PORTSMOUTH, N.H., May 03, 2024--Epredia, a global leader in precision cancer diagnostics and subsidiary of PHC Holdings Corporation (TSE: 6523), and NovaScan, Inc., a company that develops breakthrough technology for cancer detection and stratification, announce that they have signed a letter of intent for a U.S. exclusive commercial distribution agreement for MarginScan™, a medical device that will support physicians in real-time detection of non-melanoma skin cancer. Epredia has engaged Avanti
Business WireEversense® CGM System Receives iCGM Designation by the US FDA
GERMANTOWN, Md. & PARSIPPANY, N.J., April 30, 2024--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes and Ascensia Diabetes Care, a global diabetes care company, announced that Eversense® has been granted an integrated CGM (iCGM) designation by the US Food and Drug Administration (FDA).
PR NewswireSAVINGS OFFER FOR THE EVERSENSE E3 CGM EXTENDED TO COVER UNLIMITED NUMBER OF SYSTEMS
Ascensia Diabetes Care, a global diabetes care company and a subsidiary of PHC Holdings Corporation (TSE: 6523), and Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, have announced a significant extension of the Eversense Payment Assistance and Simple Savings (PASS) Program. Designed to help people in the U.S. access the Eversen
